1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: 
Outcome of studies of IIH patients treated by transverse sinus stenting
Reference^a Stenting Pressure Gradient Follow-Up Duration (mo) Headache Papilledema^b
Unilateral Bilateral Before (mm Hg) After (mm Hg) No Change Resolved or Improved Worse No Change Resolved or Improved Atrophy
Higgins et al 2003²⁰ 10 2 8–37 2–15 7–26 5 7 0 2 4 3
Owler et al 2003²¹ 4 0 12–25 0–1 5–12 0 4 0 0 4 2
Ogungbo et al 2003²² 1 0 25 ns 6 0 1 0 0 1 0
Rajpal et al 2005²³ 1 0 25 ns 6 0 1 0 0 1 0
Rohr et al 2007¹⁴ 1 0 39 1 0.25 0 1 0 0 0 0
Donnet et al 2008²⁶ 9 1 14–34 ns 6–36 2 8 0 0 10 2
Paquet et al 2008²⁷ 1 0 15 ns ns 0 1 0 0 1 0
This study 10 0 11–50 2–23 4–60 0 10 0 0 9 1
Totals 37 3 8–50 0–23 0.25–60 7 33 0 2 30 8


a Higgins et al 2002,¹⁹ Metellus et al 2005,²⁴ and Metellus et al 2007²⁵ were excluded due to uncertainty as to whether patients were reported in subsequent publications.


b Rohr et al 2007¹⁴: outcome of papilledema after stenting not specified. Higgins et al 2003²⁰: outcome of papilledema after stenting not specified for 1 patient, 4 patients did not have papilledema at presentation, and 3 patients had optic atrophy at presentation. Present study: 1 patient did not have papilledema at the time of stenting.